Boston Partners
IDYA icon

Boston Partners’s IDEAYA Biosciences IDYA Stock Holding History

Boston Partners’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13,391
Closed -$588K – 751
2024
Q1 		$588K Buy
+13,391
New +$576K ﹤0.01% 670

Other funds holding IDYA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Boston Partners's IDYA Position: Q2 2024 in Review

Boston Partners sold out of IDEAYA Biosciences (IDYA) in Q2 2024, closing a stake of 13,391 shares — an estimated $588K sold.

Boston Partners first reported a position in IDYA in Q1 2024 and held it in 1 quarter. The position peaked at $588K in Q1 2024. 199 funds tracked by Wall St. Rank hold IDYA as of Q2 2024.

  • Boston Partners reported no remaining IDEAYA Biosciences position as of Q2 2024 after selling out during the quarter.
  • Boston Partners sold 13,391 IDEAYA Biosciences shares in Q2 2024, an estimated $588K.
  • Boston Partners first reported a position in IDEAYA Biosciences in Q1 2024 and held it in 1 quarter.
  • Boston Partners's IDEAYA Biosciences position peaked at $588K in Q1 2024.
  • 199 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q2 2024.

Based on Boston Partners's 13F filing for Q2 2024, filed 14 Aug 2024.